Skip to main content

Table 2 Most frequently used medications for EIBA and EIBwA and the 2015 World Anti-Doping Agency (WADA) regulations

From: Exercise-induced bronchoconstriction: new evidence in pathogenesis, diagnosis and treatment

Treatment WADA rules Notes
Antihistamines Permitted Second generation molecules should be preferred to avoid side effects
Leukotriene modifiers Permitted  
Inhaled steroids Permitted  
Systemic steroids Prohibited in competition  
Beta-2 agonists Inhaled Salbutamol (max 1600 mcg/24H), Formoterol (max 54 mcg/24H) and Salmeterol permitted The presence in urine of salbutamol >1000 ng/mL or formoterol >40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding
All others prohibited in and out  
competition  
Mast-cell stabilizers Permitted  
Anticholinergic agents Permitted  
Immunotherapy Permitted SCIT should not be performed before or after physical exercise